Ansbert Gadicke - Net Worth and Insider Trading

Ansbert Gadicke Net Worth

The estimated net worth of Ansbert Gadicke is at least $139 Million dollars as of 2025-01-12. Ansbert Gadicke is the Director, 10% Owner of Cullinan Therapeutics Inc and owns about 7,892,819 shares of Cullinan Therapeutics Inc (CGEM) stock worth over $88 Million. Ansbert Gadicke is the 10% Owner of Harpoon Therapeutics Inc and owns about 842,285 shares of Harpoon Therapeutics Inc (HARP) stock worth over $19 Million. Ansbert Gadicke is also the 10% Owner of Repare Therapeutics Inc and owns about 11,706,178 shares of Repare Therapeutics Inc (RPTX) stock worth over $16 Million. Besides these, Ansbert Gadicke also holds TCR2 Therapeutics Inc (TCRR) , Rigel Pharmaceuticals Inc (RIGL) , Verastem Inc (VSTM) , Oncorus Inc (ONCR) . Details can be seen in Ansbert Gadicke's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Ansbert Gadicke has not made any transactions after 2023-05-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

Transaction Summary of Ansbert Gadicke

Ansbert Gadicke Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Ansbert Gadicke owns 33 companies in total, including Oncorus Inc (ONCR) , Dyne Therapeutics Inc (DYN) , and AlloVir Inc (ALVR) among others .

Click here to see the complete history of Ansbert Gadicke’s form 4 insider trades.

Insider Ownership Summary of Ansbert Gadicke

Ticker	Comapny	Transaction Date	Type of Owner
ONCR	Oncorus Inc	2020-10-06	10 percent owner
DYN	Dyne Therapeutics Inc	2020-09-16	10 percent owner
ALVR	AlloVir Inc	2020-07-29	director & 10 percent owner
		2020-07-23	director & 10 percent owner
		2021-07-12	10 percent owner
		2023-05-22	director & 10 percent owner
		2019-02-12	10 percent owner
		2017-10-04	10 percent owner
		2011-11-18	director & 10 percent owner
		2016-06-09	director
		2016-03-02	10 percent owner
		2015-10-14	10 percent owner
		2014-04-22	10 percent owner
		2014-03-10	10 percent owner
		2013-05-30	10 percent owner
		2013-07-24	10 percent owner
		2011-02-02	10 percent owner
		2012-08-11	10 percent owner
		2012-02-01	director
		2011-10-27	10 percent owner
		2010-12-14	other: Former 10% Owner
		2007-08-03	other: See explanation below
		2010-09-30	10 percent owner
		2010-03-11	10 percent owner
		2010-01-27	10 percent owner
		2009-11-05	10 percent owner
		2006-12-19	10 percent owner
		2003-12-17	10 percent owner
		2004-07-02	10 percent owner
		2004-03-10	10 percent owner
		2021-10-28	10 percent owner
		2021-04-29	10 percent owner
		2021-09-16	director & 10 percent owner

Ansbert Gadicke Latest Holdings Summary

Ansbert Gadicke currently owns a total of 7 stocks. Among these stocks, Ansbert Gadicke owns 7,892,819 shares of Cullinan Therapeutics Inc (CGEM) as of September 16, 2021, with a value of $88 Million and a weighting of 63.43%. Ansbert Gadicke owns 842,285 shares of Harpoon Therapeutics Inc (HARP) as of February 12, 2019, with a value of $19 Million and a weighting of 13.92%. Ansbert Gadicke also owns 11,706,178 shares of Repare Therapeutics Inc (RPTX) as of July 12, 2021, with a value of $16 Million and a weighting of 11.6%. The other 4 stocks TCR2 Therapeutics Inc (TCRR) , Rigel Pharmaceuticals Inc (RIGL) , Verastem Inc (VSTM) , Oncorus Inc (ONCR) have a combined weighting of 11.06% among all his current holdings.

Latest Holdings of Ansbert Gadicke

Ticker	Comapny	Latest Transaction Date	Shares Owned	Current Price ($)	Current Value ($)
CGEM	Cullinan Therapeutics Inc	2021-09-16	7,892,819	11.19	88,320,645
HARP	Harpoon Therapeutics Inc	2019-02-12	842,285	23.01	19,380,978
RPTX	Repare Therapeutics Inc	2021-07-12	11,706,178	1.38	16,154,526
TCRR	TCR2 Therapeutics Inc	2023-05-22	7,529,946	1.48	11,144,320
RIGL	Rigel Pharmaceuticals Inc	2004-07-02	183,360	16.25	2,979,600
VSTM	Verastem Inc	2012-02-01	169,444	5.73	970,914
ONCR	Oncorus Inc	2020-10-06	2,377,025	0.13	299,505

Holding Weightings of Ansbert Gadicke

Ansbert Gadicke Form 4 Trading Tracker

According to the SEC Form 4 filings, Ansbert Gadicke has made a total of 9 transactions in Cullinan Therapeutics Inc (CGEM) over the past 5 years, including 1 buys and 8 sells. The most-recent trade in Cullinan Therapeutics Inc is the sale of 3,556 shares on September 16, 2021, which brought Ansbert Gadicke around $103,337.

According to the SEC Form 4 filings, Ansbert Gadicke has made a total of 0 transactions in Harpoon Therapeutics Inc (HARP) over the past 5 years. The most-recent trade in Harpoon Therapeutics Inc is the sale of 197 shares on February 12, 2019, which brought Ansbert Gadicke around $27,594.

According to the SEC Form 4 filings, Ansbert Gadicke has made a total of 9 transactions in Repare Therapeutics Inc (RPTX) over the past 5 years, including 1 buys and 8 sells. The most-recent trade in Repare Therapeutics Inc is the sale of 62,079 shares on July 12, 2021, which brought Ansbert Gadicke around $2 Million.

More details on Ansbert Gadicke's insider transactions can be found in the Insider Trading History of Ansbert Gadicke table.

Insider Trading History of Ansbert Gadicke

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.

Total 0

Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Ansbert Gadicke Trading Performance

GuruFocus tracks the stock performance after each of Ansbert Gadicke's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Ansbert Gadicke is 14.14%. GuruFocus also compares Ansbert Gadicke's trading performance to market benchmark return within the same time period. The performance of stocks bought by Ansbert Gadicke within 3 months outperforms 1 times out of 6 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Ansbert Gadicke's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Ansbert Gadicke

Average Return

Average return per transaction

Outperforming Transactions

1 out of 6 outperforming transactions.

Each transaction is measured over a period and compared to .

	1 Month	3 Months	6 Months	1 Year	2 Years	3 Years
Return(%)	7.47
Relative Return to S&P 500(%)	4.37

Ansbert Gadicke Ownership Network

Ownership Network List of Ansbert Gadicke

No Data

Ownership Network Relation of Ansbert Gadicke

Ansbert Gadicke Owned Company Details

What does Oncorus Inc do?

Who are the key executives at Oncorus Inc?

Ansbert Gadicke is the 10 percent owner of Oncorus Inc. Other key executives at Oncorus Inc include Interim CEO Brian J. Shea , Interim CFO Alexander Nolte , and director & 10 percent owner & other: *Possible Member of 10% Group James E Flynn .

Oncorus Inc (ONCR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Oncorus Inc (ONCR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Oncorus Inc (ONCR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Oncorus Inc (ONCR)'s detailed insider trading history can be found in Insider Trading Tracker table.

Oncorus Inc Insider Transactions

No Available Data

What does Dyne Therapeutics Inc do?

Who are the key executives at Dyne Therapeutics Inc?

Ansbert Gadicke is the 10 percent owner of Dyne Therapeutics Inc. Other key executives at Dyne Therapeutics Inc include See Remarks Richard William Scalzo , See Remarks Oxana Beskrovnaya , and director & 10 percent owner Dirk Kersten .

Dyne Therapeutics Inc (DYN) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Dyne Therapeutics Inc (DYN). Other recent insider transactions involving Dyne Therapeutics Inc (DYN) include a net sale of 852,067 shares made by Dirk Kersten , a net sale of 280,316 shares made by Richard William Scalzo , and a net sale of 272,058 shares made by Susanna Gatti High .

In summary, during the past 3 months, insiders sold 482,503 shares of Dyne Therapeutics Inc (DYN) in total and bought 0 shares, with a net sale of 482,503 shares. During the past 18 months, 8,033,921 shares of Dyne Therapeutics Inc (DYN) were sold and 1,746,285 shares were bought by its insiders, resulting in a net sale of 6,287,636 shares.

Dyne Therapeutics Inc (DYN)'s detailed insider trading history can be found in Insider Trading Tracker table.

Dyne Therapeutics Inc Insider Transactions

No Available Data

What does AlloVir Inc do?

Who are the key executives at AlloVir Inc?

Ansbert Gadicke is the director & 10 percent owner of AlloVir Inc. Other key executives at AlloVir Inc include director & 10 percent owner & See Remarks Vikas Sinha , General Counsel Edward Miller , and Chief Accounting Officer Brett R Hagen .

AlloVir Inc (ALVR) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in AlloVir Inc (ALVR). Other recent insider transactions involving AlloVir Inc (ALVR) include a net sale of 192,278 shares made by Diana Brainard , a net sale of 61,006 shares made by Brett R Hagen , and a net sale of 82,295 shares made by Vikas Sinha .

In summary, during the past 3 months, insiders sold 48,096 shares of AlloVir Inc (ALVR) in total and bought 0 shares, with a net sale of 48,096 shares. During the past 18 months, 360,038 shares of AlloVir Inc (ALVR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 360,038 shares.

AlloVir Inc (ALVR)'s detailed insider trading history can be found in Insider Trading Tracker table.

AlloVir Inc Insider Transactions

No Available Data

What does ITeos Therapeutics Inc do?

Who are the key executives at ITeos Therapeutics Inc?

Ansbert Gadicke is the director & 10 percent owner of ITeos Therapeutics Inc. Other key executives at ITeos Therapeutics Inc include Chief Financial Officer Matthew Gall , other: See remarks Joseph Lewis , and other: See remarks Boxer Asset Management Inc. .

ITeos Therapeutics Inc (ITOS) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in ITeos Therapeutics Inc (ITOS). Other recent insider transactions involving ITeos Therapeutics Inc (ITOS) include a net purchase of 10,000 shares made by Matthew Gall , and a net sale of 350,000 shares made by Boxer Capital, Llc .

In summary, during the past 3 months, insiders sold 0 shares of ITeos Therapeutics Inc (ITOS) in total and bought 5,000 shares, with a net purchase of 5,000 shares. During the past 18 months, 350,000 shares of ITeos Therapeutics Inc (ITOS) were sold and 10,000 shares were bought by its insiders, resulting in a net sale of 340,000 shares.

ITeos Therapeutics Inc (ITOS)'s detailed insider trading history can be found in Insider Trading Tracker table.

ITeos Therapeutics Inc Insider Transactions

No Available Data

What does Repare Therapeutics Inc do?

Who are the key executives at Repare Therapeutics Inc?

Ansbert Gadicke is the 10 percent owner of Repare Therapeutics Inc. Other key executives at Repare Therapeutics Inc include EVP & Chief Medical Officer Maria Koehler , EVP & Chief Science Officer Michael Zinda , and EVP & Chief Financial Officer Steve Forte .

Repare Therapeutics Inc (RPTX) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Repare Therapeutics Inc (RPTX). Other recent insider transactions involving Repare Therapeutics Inc (RPTX) include a net purchase of 2,011,010 shares made by Biotechnology Value Fund L P , a net sale of 13,091 shares made by Lloyd Mitchell Segal , and a net sale of 4,089 shares made by Steve Forte .

In summary, during the past 3 months, insiders sold 0 shares of Repare Therapeutics Inc (RPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 21,690 shares of Repare Therapeutics Inc (RPTX) were sold and 2,011,010 shares were bought by its insiders, resulting in a net purchase of 1,989,320 shares.

Repare Therapeutics Inc (RPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Repare Therapeutics Inc Insider Transactions

No Available Data

What does TCR2 Therapeutics Inc do?

Who are the key executives at TCR2 Therapeutics Inc?

Ansbert Gadicke is the director & 10 percent owner of TCR2 Therapeutics Inc. Other key executives at TCR2 Therapeutics Inc include 10 percent owner Kevin C Tang , 10 percent owner Mpm Asset Management Llc , and 10 percent owner Tang Capital Management Llc .

TCR2 Therapeutics Inc (TCRR) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TCR2 Therapeutics Inc (TCRR) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TCR2 Therapeutics Inc (TCRR) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TCR2 Therapeutics Inc (TCRR)'s detailed insider trading history can be found in Insider Trading Tracker table.

TCR2 Therapeutics Inc Insider Transactions

No Available Data

What does Harpoon Therapeutics Inc do?

Who are the key executives at Harpoon Therapeutics Inc?

Ansbert Gadicke is the 10 percent owner of Harpoon Therapeutics Inc. Other key executives at Harpoon Therapeutics Inc include 10 percent owner Vijay K Lathi , Chief Medical Officer Luke Nathaniel Walker , and Principal Fin. & Acctng Ofc. Frank J Lanza .

Harpoon Therapeutics Inc (HARP) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Harpoon Therapeutics Inc (HARP). Other recent insider transactions involving Harpoon Therapeutics Inc (HARP) include a net purchase of 21,397,205 shares made by Merck & Co., Inc. ,

In summary, during the past 3 months, insiders sold 0 shares of Harpoon Therapeutics Inc (HARP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Harpoon Therapeutics Inc (HARP) were sold and 21,397,205 shares were bought by its insiders, resulting in a net purchase of 21,397,205 shares.

Harpoon Therapeutics Inc (HARP)'s detailed insider trading history can be found in Insider Trading Tracker table.

Harpoon Therapeutics Inc Insider Transactions

No Available Data

What does Rhythm Pharmaceuticals Inc do?

Who are the key executives at Rhythm Pharmaceuticals Inc?

Ansbert Gadicke is the 10 percent owner of Rhythm Pharmaceuticals Inc. Other key executives at Rhythm Pharmaceuticals Inc include EVP & Head of North America Jennifer Chien , Chief Technical Officer Joseph Shulman , and Chief Human Resources Officer Pamela J. Cramer .

Rhythm Pharmaceuticals Inc (RYTM) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Rhythm Pharmaceuticals Inc (RYTM). Other recent insider transactions involving Rhythm Pharmaceuticals Inc (RYTM) include a net sale of 184,943 shares made by Joseph Shulman , a net sale of 145,755 shares made by Jennifer Chien , and a net sale of 85,162 shares made by Pamela J. Cramer .

In summary, during the past 3 months, insiders sold 89,517 shares of Rhythm Pharmaceuticals Inc (RYTM) in total and bought 0 shares, with a net sale of 89,517 shares. During the past 18 months, 672,183 shares of Rhythm Pharmaceuticals Inc (RYTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 672,183 shares.

Rhythm Pharmaceuticals Inc (RYTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rhythm Pharmaceuticals Inc Insider Transactions

No Available Data

What does Radius Health Inc do?

Who are the key executives at Radius Health Inc?

Ansbert Gadicke is the director & 10 percent owner of Radius Health Inc. Other key executives at Radius Health Inc include director & CEO and President G. Kelly Martin , Senior Vice President Elizabeth Messersmith , and Vice President & Sales Danielle Holtschlag .

Radius Health Inc (RDUS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Radius Health Inc (RDUS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Radius Health Inc (RDUS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Radius Health Inc (RDUS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Radius Health Inc Insider Transactions

No Available Data

What does Chiasma Inc do?

Who are the key executives at Chiasma Inc?

Ansbert Gadicke is the director of Chiasma Inc. Other key executives at Chiasma Inc include director & Chief Executive Officer Raj Kannan , EVP & Chief Commerical Officer Anand Varadan , and President Mark J. Fitzpatrick .

Chiasma Inc (CHMA) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Chiasma Inc (CHMA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Chiasma Inc (CHMA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Chiasma Inc (CHMA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Chiasma Inc Insider Transactions

No Available Data

What does Syndax Pharmaceuticals Inc do?

Who are the key executives at Syndax Pharmaceuticals Inc?

Ansbert Gadicke is the 10 percent owner of Syndax Pharmaceuticals Inc. Other key executives at Syndax Pharmaceuticals Inc include Chief Financial Officer Keith A. Goldan , director & Chief Executive Officer Briggs Morrison , and President & Head of R&D Neil Gallagher .

Syndax Pharmaceuticals Inc (SNDX) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Syndax Pharmaceuticals Inc (SNDX). Other recent insider transactions involving Syndax Pharmaceuticals Inc (SNDX) include a net sale of 83,000 shares made by William Meury , a net sale of 52,855 shares made by Briggs Morrison , and a net purchase of 1,250 shares made by Keith A. Goldan .

In summary, during the past 3 months, insiders sold 0 shares of Syndax Pharmaceuticals Inc (SNDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 135,855 shares of Syndax Pharmaceuticals Inc (SNDX) were sold and 1,250 shares were bought by its insiders, resulting in a net sale of 134,605 shares.

Syndax Pharmaceuticals Inc (SNDX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Syndax Pharmaceuticals Inc Insider Transactions

No Available Data

What does Avalo Therapeutics Inc do?

Who are the key executives at Avalo Therapeutics Inc?

Ansbert Gadicke is the 10 percent owner of Avalo Therapeutics Inc. Other key executives at Avalo Therapeutics Inc include director & 10 percent owner Armistice Capital Master Fund Ltd. , 10 percent owner Caissa Capital Management Ltd. , and Interim CFO Christopher Ryan Sullivan .

Avalo Therapeutics Inc (AVTX) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Avalo Therapeutics Inc (AVTX). Other recent insider transactions involving Avalo Therapeutics Inc (AVTX) include a net purchase of 1,000 shares made by June Sherie Almenoff ,

In summary, during the past 3 months, insiders sold 0 shares of Avalo Therapeutics Inc (AVTX) in total and bought 1,000 shares, with a net purchase of 1,000 shares. During the past 18 months, 0 shares of Avalo Therapeutics Inc (AVTX) were sold and 1,000 shares were bought by its insiders, resulting in a net purchase of 1,000 shares.

Avalo Therapeutics Inc (AVTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Avalo Therapeutics Inc Insider Transactions

No Available Data

What does TriVascular Technologies Inc do?

Who are the key executives at TriVascular Technologies Inc?

Ansbert Gadicke is the 10 percent owner of TriVascular Technologies Inc. Other key executives at TriVascular Technologies Inc include 10 percent owner Krishna Kittu Kolluri , VP & Gen. Counsel and Secretary Kimberley A. Elting , and Chief Technology Officer Michael V. Chobotov .

TriVascular Technologies Inc (TRIV) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of TriVascular Technologies Inc (TRIV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of TriVascular Technologies Inc (TRIV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

TriVascular Technologies Inc (TRIV)'s detailed insider trading history can be found in Insider Trading Tracker table.

TriVascular Technologies Inc Insider Transactions

No Available Data

What does Aratana Therapeutics Inc do?

Who are the key executives at Aratana Therapeutics Inc?

Ansbert Gadicke is the 10 percent owner of Aratana Therapeutics Inc. Other key executives at Aratana Therapeutics Inc include 10 percent owner Broadfin Healthcare Master Fund Ltd , 10 percent owner Broadfin Capital, Llc , and 10 percent owner Kevin Kotler .

Aratana Therapeutics Inc (PETX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Aratana Therapeutics Inc (PETX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Aratana Therapeutics Inc (PETX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Aratana Therapeutics Inc (PETX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Aratana Therapeutics Inc Insider Transactions

No Available Data

What does Epizyme Inc do?

Who are the key executives at Epizyme Inc?

Ansbert Gadicke is the 10 percent owner of Epizyme Inc. Other key executives at Epizyme Inc include Chief Scientific Officer Jeffery Kutok , Chief Operating Officer Jerald Korn , and Corporate Controller Joseph Beaulieu .

Epizyme Inc (EPZM) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Epizyme Inc (EPZM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Epizyme Inc (EPZM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Epizyme Inc (EPZM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Epizyme Inc Insider Transactions

No Available Data

What does Histogen Inc do?

Who are the key executives at Histogen Inc?

Ansbert Gadicke is the 10 percent owner of Histogen Inc. Other key executives at Histogen Inc include See Remarks Joyce Reyes , director & See Remarks Richard W Pascoe , and See Remarks Moya Daniels .

Histogen Inc (HSTOQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Histogen Inc (HSTOQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Histogen Inc (HSTOQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Histogen Inc (HSTOQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Histogen Inc Insider Transactions

No Available Data

What does Pacira BioSciences Inc do?

Who are the key executives at Pacira BioSciences Inc?

Ansbert Gadicke is the 10 percent owner of Pacira BioSciences Inc. Other key executives at Pacira BioSciences Inc include Chief Clinical Officer Jonathan Slonin , Chief Operating Officer Daryl Gaugler , and CAO and General Counsel Kristen Marie Williams .

Pacira BioSciences Inc (PCRX) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Pacira BioSciences Inc (PCRX). Other recent insider transactions involving Pacira BioSciences Inc (PCRX) include a net sale of 9,672 shares made by Jonathan Slonin , a net purchase of 8,312 shares made by Marcelo Bigal , and a net sale of 2,000 shares made by Daryl Gaugler .

In summary, during the past 3 months, insiders sold 1,379 shares of Pacira BioSciences Inc (PCRX) in total and bought 0 shares, with a net sale of 1,379 shares. During the past 18 months, 143,806 shares of Pacira BioSciences Inc (PCRX) were sold and 20,976 shares were bought by its insiders, resulting in a net sale of 122,830 shares.

Pacira BioSciences Inc (PCRX)'s detailed insider trading history can be found in Insider Trading Tracker table.

Pacira BioSciences Inc Insider Transactions

No Available Data

What does Humanigen Inc do?

Who are the key executives at Humanigen Inc?

Ansbert Gadicke is the 10 percent owner of Humanigen Inc. Other key executives at Humanigen Inc include 10 percent owner Dale Chappell , Chief Medical Officer Adrian Kilcoyne , and Chief Commercial Officer Edward P. Jordan .

Humanigen Inc (HGENQ) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Humanigen Inc (HGENQ). Other recent insider transactions involving Humanigen Inc (HGENQ) include a net sale of 386,350 shares made by Dale Chappell ,

In summary, during the past 3 months, insiders sold 0 shares of Humanigen Inc (HGENQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 386,350 shares of Humanigen Inc (HGENQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 386,350 shares.

Humanigen Inc (HGENQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Humanigen Inc Insider Transactions

No Available Data

What does Verastem Inc do?

Who are the key executives at Verastem Inc?

Ansbert Gadicke is the director of Verastem Inc. Other key executives at Verastem Inc include Vice President of Finance Daniel Calkins , Chief Operating Officer Dan Paterson , and Chief Financial Officer Robert E. Gagnon .

Verastem Inc (VSTM) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Verastem Inc (VSTM). Other recent insider transactions involving Verastem Inc (VSTM) include a net sale of 736 shares made by Daniel Calkins , a net sale of 20,890 shares made by Robert E. Gagnon , and a net sale of 6,617 shares made by Dan Paterson .

In summary, during the past 3 months, insiders sold 2,682 shares of Verastem Inc (VSTM) in total and bought 0 shares, with a net sale of 2,682 shares. During the past 18 months, 33,359 shares of Verastem Inc (VSTM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 33,359 shares.

Verastem Inc (VSTM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Verastem Inc Insider Transactions

No Available Data

What does EPIRUS Biopharmaceuticals Inc do?

Who are the key executives at EPIRUS Biopharmaceuticals Inc?

Ansbert Gadicke is the 10 percent owner of EPIRUS Biopharmaceuticals Inc. Other key executives at EPIRUS Biopharmaceuticals Inc include Chief Business Officer Vincent Aurentz , Chief Financial Officer Thomas A. Shea , and director & Chief Executive Officer Amit Munshi .

EPIRUS Biopharmaceuticals Inc (EPRSQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of EPIRUS Biopharmaceuticals Inc (EPRSQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

EPIRUS Biopharmaceuticals Inc (EPRSQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

EPIRUS Biopharmaceuticals Inc Insider Transactions

No Available Data

What does Reshape Lifesciences Inc do?

Who are the key executives at Reshape Lifesciences Inc?

Ansbert Gadicke is the other: Former 10% Owner of Reshape Lifesciences Inc. Other key executives at Reshape Lifesciences Inc include Chief Financial Officer Thomas Stankovich , President and CEO Barton P. Bandy , and director & Chairman & President and CEO Dan W Gladney .

Reshape Lifesciences Inc (RSLS) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Reshape Lifesciences Inc (RSLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Reshape Lifesciences Inc (RSLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Reshape Lifesciences Inc (RSLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

Reshape Lifesciences Inc Insider Transactions

No Available Data

What does Altimmune Inc do?

Who are the key executives at Altimmune Inc?

Ansbert Gadicke is the other: See explanation below of Altimmune Inc. Other key executives at Altimmune Inc include Chief Financial Officer Richard I Eisenstadt , Chief Medical Officer Matthew Scott Harris , and Chief Business Officer Raymond M Jordt .

Altimmune Inc (ALT) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Altimmune Inc (ALT). Other recent insider transactions involving Altimmune Inc (ALT) include a net sale of 15,711 shares made by David Drutz ,

In summary, during the past 3 months, insiders sold 0 shares of Altimmune Inc (ALT) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 16,011 shares of Altimmune Inc (ALT) were sold and 300 shares were bought by its insiders, resulting in a net sale of 15,711 shares.

Altimmune Inc (ALT)'s detailed insider trading history can be found in Insider Trading Tracker table.

Altimmune Inc Insider Transactions

No Available Data

What does ARYx Therapeutics Inc do?

Who are the key executives at ARYx Therapeutics Inc?

Ansbert Gadicke is the 10 percent owner of ARYx Therapeutics Inc. Other key executives at ARYx Therapeutics Inc include 10 percent owner Krishna Kittu Kolluri , 10 percent owner Growth Equity Opportunities Fund, Llc , and 10 percent owner Mark W Perry .

ARYx Therapeutics Inc (ARYX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of ARYx Therapeutics Inc (ARYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of ARYx Therapeutics Inc (ARYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

ARYx Therapeutics Inc (ARYX)'s detailed insider trading history can be found in Insider Trading Tracker table.

ARYx Therapeutics Inc Insider Transactions

No Available Data

What does AVEO Pharmaceuticals Inc do?

Who are the key executives at AVEO Pharmaceuticals Inc?

Ansbert Gadicke is the 10 percent owner of AVEO Pharmaceuticals Inc. Other key executives at AVEO Pharmaceuticals Inc include Chief Operating Officer Jebediah Ledell , director & President & CEO Michael P Bailey , and Chief Commercial Officer Michael Ferraresso .

AVEO Pharmaceuticals Inc (AVEO) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of AVEO Pharmaceuticals Inc (AVEO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of AVEO Pharmaceuticals Inc (AVEO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

AVEO Pharmaceuticals Inc (AVEO)'s detailed insider trading history can be found in Insider Trading Tracker table.

AVEO Pharmaceuticals Inc Insider Transactions

No Available Data

What does Metabasis Therapeutics Inc do?

Who are the key executives at Metabasis Therapeutics Inc?

Ansbert Gadicke is the 10 percent owner of Metabasis Therapeutics Inc. Other key executives at Metabasis Therapeutics Inc include 10 percent owner Michael Steinmetz , 10 percent owner Mpm Asset Management Investors 2000b Llc , and 10 percent owner Mpm Bioventures Ii Gmbh & Co Parallel Beteiligungs Kg .

Metabasis Therapeutics Inc (LGNZZ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Metabasis Therapeutics Inc (LGNZZ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Metabasis Therapeutics Inc (LGNZZ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Metabasis Therapeutics Inc (LGNZZ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Metabasis Therapeutics Inc Insider Transactions

No Available Data

What does Poniard Pharmaceuticals Inc do?

Who are the key executives at Poniard Pharmaceuticals Inc?

Ansbert Gadicke is the 10 percent owner of Poniard Pharmaceuticals Inc. Other key executives at Poniard Pharmaceuticals Inc include President & CMO Michael S Perry , director & Chief Executive Officer Ron Martell , and director & 10 percent owner Simon Nicholas J Iii .

Poniard Pharmaceuticals Inc (PARD) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Poniard Pharmaceuticals Inc (PARD) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Poniard Pharmaceuticals Inc (PARD) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Poniard Pharmaceuticals Inc (PARD)'s detailed insider trading history can be found in Insider Trading Tracker table.

Poniard Pharmaceuticals Inc Insider Transactions

No Available Data

What does Affymax Inc do?

Who are the key executives at Affymax Inc?

Ansbert Gadicke is the 10 percent owner of Affymax Inc. Other key executives at Affymax Inc include Chief Financial Officer Mark G Thompson , Chief Commercial Officer Jeffrey H Knapp , and Chief Financial Officer Herb Cross .

Affymax Inc (AFFY) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Affymax Inc (AFFY) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Affymax Inc (AFFY) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Affymax Inc (AFFY)'s detailed insider trading history can be found in Insider Trading Tracker table.

Affymax Inc Insider Transactions

No Available Data

What does Acorda Therapeutics Inc do?

Who are the key executives at Acorda Therapeutics Inc?

Ansbert Gadicke is the 10 percent owner of Acorda Therapeutics Inc. Other key executives at Acorda Therapeutics Inc include CEO and President Ron Cohen , Chief Financial Officer Michael A Gesser , and General Counsel Neil S. Belloff .

Acorda Therapeutics Inc (ACORQ) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Acorda Therapeutics Inc (ACORQ) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Acorda Therapeutics Inc (ACORQ) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Acorda Therapeutics Inc (ACORQ)'s detailed insider trading history can be found in Insider Trading Tracker table.

Acorda Therapeutics Inc Insider Transactions

No Available Data

What does Rigel Pharmaceuticals Inc do?

Who are the key executives at Rigel Pharmaceuticals Inc?

Ansbert Gadicke is the 10 percent owner of Rigel Pharmaceuticals Inc. Other key executives at Rigel Pharmaceuticals Inc include EVP & Chief Financial Officer Dean L Schorno , Sr VP of Bus Dev and Com Ops Raul R Rodriguez , and EVP & Chief Commercial Officer David A Santos .

Rigel Pharmaceuticals Inc (RIGL) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Rigel Pharmaceuticals Inc (RIGL). Other recent insider transactions involving Rigel Pharmaceuticals Inc (RIGL) include a net sale of 52,894 shares made by Raul R Rodriguez , a net sale of 14,519 shares made by David A Santos , and a net sale of 12,628 shares made by Dean L Schorno .

In summary, during the past 3 months, insiders sold 0 shares of Rigel Pharmaceuticals Inc (RIGL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 8,004 shares of Rigel Pharmaceuticals Inc (RIGL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 8,004 shares.

Rigel Pharmaceuticals Inc (RIGL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Rigel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Cyclacel Pharmaceuticals Inc do?

Who are the key executives at Cyclacel Pharmaceuticals Inc?

Ansbert Gadicke is the 10 percent owner of Cyclacel Pharmaceuticals Inc. Other key executives at Cyclacel Pharmaceuticals Inc include director & President & C.E.O. Spiro Rombotis , director & E.V.P. & Finance & C.O.O. Paul Mcbarron , and Chief Medical Officer Mark Kirschbaum .

Cyclacel Pharmaceuticals Inc (CYCC) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Cyclacel Pharmaceuticals Inc (CYCC). Other recent insider transactions involving Cyclacel Pharmaceuticals Inc (CYCC) include a net purchase of 6,070 shares made by Spiro Rombotis , and a net purchase of 1,886 shares made by Paul Mcbarron .

In summary, during the past 3 months, insiders sold 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Cyclacel Pharmaceuticals Inc (CYCC) were sold and 7,956 shares were bought by its insiders, resulting in a net purchase of 7,956 shares.

Cyclacel Pharmaceuticals Inc (CYCC)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cyclacel Pharmaceuticals Inc Insider Transactions

No Available Data

What does Entrada Therapeutics Inc do?

Who are the key executives at Entrada Therapeutics Inc?

Ansbert Gadicke is the 10 percent owner of Entrada Therapeutics Inc. Other key executives at Entrada Therapeutics Inc include 10 percent owner Mpm Bioventures 2018, L.p. , 10 percent owner Mpm Bioventures 2014, L.p. , and Chief Scientific Officer Natarajan Sethuraman .

Entrada Therapeutics Inc (TRDA) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Entrada Therapeutics Inc (TRDA). Other recent insider transactions involving Entrada Therapeutics Inc (TRDA) include a net sale of 12,900 shares made by Dipal Doshi , a net sale of 62,279 shares made by Natarajan Sethuraman , and a net sale of 37,126 shares made by Kory James Wentworth .

In summary, during the past 3 months, insiders sold 142,900 shares of Entrada Therapeutics Inc (TRDA) in total and bought 0 shares, with a net sale of 142,900 shares. During the past 18 months, 262,396 shares of Entrada Therapeutics Inc (TRDA) were sold and 45,368 shares were bought by its insiders, resulting in a net sale of 217,028 shares.

Entrada Therapeutics Inc (TRDA)'s detailed insider trading history can be found in Insider Trading Tracker table.

Entrada Therapeutics Inc Insider Transactions

No Available Data

What does Werewolf Therapeutics Inc do?

Who are the key executives at Werewolf Therapeutics Inc?

Ansbert Gadicke is the 10 percent owner of Werewolf Therapeutics Inc. Other key executives at Werewolf Therapeutics Inc include director & 10 percent owner Ra Capital Healthcare Fund Lp , Chief Technology Officer Chulani Karunatilake , and Chief Operating Officer Reid Leonard .

Werewolf Therapeutics Inc (HOWL) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Werewolf Therapeutics Inc (HOWL) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Werewolf Therapeutics Inc (HOWL) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Werewolf Therapeutics Inc (HOWL)'s detailed insider trading history can be found in Insider Trading Tracker table.

Werewolf Therapeutics Inc Insider Transactions

No Available Data

What does Cullinan Therapeutics Inc do?

Who are the key executives at Cullinan Therapeutics Inc?

Ansbert Gadicke is the director & 10 percent owner of Cullinan Therapeutics Inc. Other key executives at Cullinan Therapeutics Inc include See Remarks Jennifer Michaelson , director & President and CEO Nadim Ahmed , and Chief Medical Officer Jeffrey Alan Jones .

Cullinan Therapeutics Inc (CGEM) Insider Trades Summary

Over the past 18 months, Ansbert Gadicke made no insider transaction in Cullinan Therapeutics Inc (CGEM). Other recent insider transactions involving Cullinan Therapeutics Inc (CGEM) include a net sale of 102,239 shares made by Jennifer Michaelson , a net sale of 120,000 shares made by Savill Corrine , and a net sale of 6,878 shares made by Jeffrey Alan Jones .

In summary, during the past 3 months, insiders sold 36,696 shares of Cullinan Therapeutics Inc (CGEM) in total and bought 0 shares, with a net sale of 36,696 shares. During the past 18 months, 251,205 shares of Cullinan Therapeutics Inc (CGEM) were sold and 0 shares were bought by its insiders, resulting in a net sale of 251,205 shares.

Cullinan Therapeutics Inc (CGEM)'s detailed insider trading history can be found in Insider Trading Tracker table.

Cullinan Therapeutics Inc Insider Transactions

No Available Data

Ansbert Gadicke Mailing Address

Above is the net worth, insider trading, and ownership report for Ansbert Gadicke. You might contact Ansbert Gadicke via mailing address: The John Hancock Tower, 200 Clarendon Street, 54th Floor, Boston Ma 02116.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.